Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
At 22C, degradation proceeds roughly 4x faster than at 4C
Clinical trial data showed similar weight loss outcomes between formulations when treatment was adhered to
The copay coupon scheme is lucrative for pharmaceutical companies, which disburse money to subsidize patient copays as a form of what they characterize as charity
